Amid the phasing out of animal experimentation by the Trump administration, biotech startup R3 Bio has introduced a novel approach to replace lab animals with genetically-engineered ‘organ sacks.’ These nonsentient structures mimic complete organ systems without brains, aiming to address ethical concerns associated with traditional animal testing methods. R3 Bio’s vision includes developing human versions of these organ systems, offering a potential ethical and scalable solution for medical research and organ transplantation needs.
CEO Boyang Wang of Immortal Dragons, a longevity fund supporting R3, sees organ replacement as a key strategy for human longevity. By creating headless, nonsentient bodyoids, the startup aims to provide a sustainable organ source for individuals in need. R3 Bio’s initial focus lies on producing monkey organ sacks, highlighting the potential to improve drug testing processes by utilizing more ethical and efficient models.
While monkeys have played a crucial role in testing new drugs, their scarcity and ethical concerns have prompted the exploration of alternative methods like organ sacks. R3 Bio’s innovative approach aligns with the principles of humane experimentation, emphasizing replacement, reduction, and refinement in research practices.
Source: WIRED